Detalhe da pesquisa
1.
Drivers and barriers to COVID-19 vaccination in Australians with cancer.
Support Care Cancer
; 31(8): 479, 2023 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37477843
2.
Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: Results from a multi-centre cohort study.
Mycoses
; 64(1): 30-34, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32885525
3.
Prospective comprehensive profiling of immune responses to COVID-19 vaccination in patients on zanubrutinib therapy.
EJHaem
; 4(1): 216-220, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36819189
4.
Evolution of Humoral and Cellular Immunity Post-Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab.
Open Forum Infect Dis
; 10(11): ofad550, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-38023562
5.
COVID-19 infection among patients with cancer in Australia from 2020 to 2022: a national multicentre cohort study.
Lancet Reg Health West Pac
; : 100824, 2023 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37360862
6.
Robust SARS-CoV-2 T cell responses with common TCRαß motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells.
Cell Rep Med
; 4(4): 101017, 2023 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37030296
7.
Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies.
Clin Lymphoma Myeloma Leuk
; 21(7): 444-450.e3, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33722538